NEW YORK (GenomeWeb News) – Dako announced late on Monday that the US Food and Drug Administration has approved its HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's breast cancer drug Perjeta (pertuzumab).

FDA also approved the drug.

Dako's assays will be used to identify patients with HER2-positive metastatic breast cancer who may be eligible for treatment with Perjeta and are available immediately.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.